Cargando…

Development and validation of web calculators to predict early recurrence and long-term survival in patients with duodenal papilla carcinoma after pancreaticoduodenectomy

BACKGROUND: Duodenal papilla carcinoma (DPC) is prone to relapse even after radical pancreaticoduodenectomy (PD) (including robotic, laparoscopic and open approach). This study aimed to develop web calculators to predict early recurrence (ER) (within two years after surgery) and long-term survival i...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Guangsheng, Xu, Shuai, Kong, Junjie, He, Jingyi, Liu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10662559/
https://www.ncbi.nlm.nih.gov/pubmed/37985973
http://dx.doi.org/10.1186/s12885-023-11632-5
_version_ 1785148562688966656
author Yu, Guangsheng
Xu, Shuai
Kong, Junjie
He, Jingyi
Liu, Jun
author_facet Yu, Guangsheng
Xu, Shuai
Kong, Junjie
He, Jingyi
Liu, Jun
author_sort Yu, Guangsheng
collection PubMed
description BACKGROUND: Duodenal papilla carcinoma (DPC) is prone to relapse even after radical pancreaticoduodenectomy (PD) (including robotic, laparoscopic and open approach). This study aimed to develop web calculators to predict early recurrence (ER) (within two years after surgery) and long-term survival in patients with DPC after PD. METHODS: Patients with DPC after radical PD were included. Univariate and multivariate logistic regression analyses were used to identify independent risk factors. Two web calculators were developed based on independent risk factors in the training cohort and then tested in the validation cohort. RESULTS: Of the 251 patients who met the inclusion criteria, 180 and 71 patients were enrolled in the training and validation cohorts, respectively. Multivariate logistic regression analysis revealed that tumor size [Odds Ratio (OR) 1.386; 95% confidence interval (CI) 1070–1.797; P = 0.014]; number of lymph node metastasis (OR 2.535; 95% CI 1.114–5.769; P = 0.027), perineural invasion (OR 3.078; 95% CI 1.147–8.257; P = 0.026), and tumor differentiation (OR 3.552; 95% CI 1.132–11.152; P = 0.030) were independent risk factors for ER. Nomogram based on the above four factors achieved good C-statistics of 0.759 and 0.729 in predicting ER in the training and the validation cohorts, respectively. Time-dependent ROC analysis (timeROC) and decision curve analysis (DCA) revealed that the nomogram provided superior diagnostic capacity and net benefit compared with single variable. CONCLUSIONS: This study developed and validated two web calculators that can predict ER and long-term survival in patients with DPC with high degree of stability and accuracy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-11632-5.
format Online
Article
Text
id pubmed-10662559
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106625592023-11-20 Development and validation of web calculators to predict early recurrence and long-term survival in patients with duodenal papilla carcinoma after pancreaticoduodenectomy Yu, Guangsheng Xu, Shuai Kong, Junjie He, Jingyi Liu, Jun BMC Cancer Research BACKGROUND: Duodenal papilla carcinoma (DPC) is prone to relapse even after radical pancreaticoduodenectomy (PD) (including robotic, laparoscopic and open approach). This study aimed to develop web calculators to predict early recurrence (ER) (within two years after surgery) and long-term survival in patients with DPC after PD. METHODS: Patients with DPC after radical PD were included. Univariate and multivariate logistic regression analyses were used to identify independent risk factors. Two web calculators were developed based on independent risk factors in the training cohort and then tested in the validation cohort. RESULTS: Of the 251 patients who met the inclusion criteria, 180 and 71 patients were enrolled in the training and validation cohorts, respectively. Multivariate logistic regression analysis revealed that tumor size [Odds Ratio (OR) 1.386; 95% confidence interval (CI) 1070–1.797; P = 0.014]; number of lymph node metastasis (OR 2.535; 95% CI 1.114–5.769; P = 0.027), perineural invasion (OR 3.078; 95% CI 1.147–8.257; P = 0.026), and tumor differentiation (OR 3.552; 95% CI 1.132–11.152; P = 0.030) were independent risk factors for ER. Nomogram based on the above four factors achieved good C-statistics of 0.759 and 0.729 in predicting ER in the training and the validation cohorts, respectively. Time-dependent ROC analysis (timeROC) and decision curve analysis (DCA) revealed that the nomogram provided superior diagnostic capacity and net benefit compared with single variable. CONCLUSIONS: This study developed and validated two web calculators that can predict ER and long-term survival in patients with DPC with high degree of stability and accuracy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-11632-5. BioMed Central 2023-11-20 /pmc/articles/PMC10662559/ /pubmed/37985973 http://dx.doi.org/10.1186/s12885-023-11632-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Yu, Guangsheng
Xu, Shuai
Kong, Junjie
He, Jingyi
Liu, Jun
Development and validation of web calculators to predict early recurrence and long-term survival in patients with duodenal papilla carcinoma after pancreaticoduodenectomy
title Development and validation of web calculators to predict early recurrence and long-term survival in patients with duodenal papilla carcinoma after pancreaticoduodenectomy
title_full Development and validation of web calculators to predict early recurrence and long-term survival in patients with duodenal papilla carcinoma after pancreaticoduodenectomy
title_fullStr Development and validation of web calculators to predict early recurrence and long-term survival in patients with duodenal papilla carcinoma after pancreaticoduodenectomy
title_full_unstemmed Development and validation of web calculators to predict early recurrence and long-term survival in patients with duodenal papilla carcinoma after pancreaticoduodenectomy
title_short Development and validation of web calculators to predict early recurrence and long-term survival in patients with duodenal papilla carcinoma after pancreaticoduodenectomy
title_sort development and validation of web calculators to predict early recurrence and long-term survival in patients with duodenal papilla carcinoma after pancreaticoduodenectomy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10662559/
https://www.ncbi.nlm.nih.gov/pubmed/37985973
http://dx.doi.org/10.1186/s12885-023-11632-5
work_keys_str_mv AT yuguangsheng developmentandvalidationofwebcalculatorstopredictearlyrecurrenceandlongtermsurvivalinpatientswithduodenalpapillacarcinomaafterpancreaticoduodenectomy
AT xushuai developmentandvalidationofwebcalculatorstopredictearlyrecurrenceandlongtermsurvivalinpatientswithduodenalpapillacarcinomaafterpancreaticoduodenectomy
AT kongjunjie developmentandvalidationofwebcalculatorstopredictearlyrecurrenceandlongtermsurvivalinpatientswithduodenalpapillacarcinomaafterpancreaticoduodenectomy
AT hejingyi developmentandvalidationofwebcalculatorstopredictearlyrecurrenceandlongtermsurvivalinpatientswithduodenalpapillacarcinomaafterpancreaticoduodenectomy
AT liujun developmentandvalidationofwebcalculatorstopredictearlyrecurrenceandlongtermsurvivalinpatientswithduodenalpapillacarcinomaafterpancreaticoduodenectomy